Our new product, the recombinant H9N2 influenza vaccine designed specifically for avian, is currently undergoing final stages of pharmaceutic and supplementary testing. This vaccine is based on yeast-based vaccines and produced using advanced genetic engineering technology. It is recognized as the first recombinant vaccine developed in Iran. ( Source )

This project is a result of a scientific collaboration between Ferdowsi University of Mashhad and the University of Tehran. The related doctoral thesis was awarded the top national thesis ranking in 2024. Source )

The vaccine aims to enhance immunity and provide effective protection against various strains of H9N2 influenza in avian, marking a significant advancement in modern vaccine development.